BioSpace News Archive

According to a new market report published by Persistence Market Research “Global Market Study on Compression Therapy – Asia to Witness Highest Growth by 2020”, the global compression therapy market was valued at USD 2,377.8 million in 2014 and is expected to expand at a CAGR of 5.2% from 2014 to 2020, to reach USD 3,232.3 million by 2020.

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer

Sientra, Inc., a diversified medical aesthetics company, announced that it has closed a $60 million convertible notes financing with a fund managed by Deerfield Management Company L.P..

Universal Health Services, Inc. (NYSE: UHS) announced today that Steve Filton, Executive Vice President and Chief Financial Officer will present at the virtual Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 10:45am

Synlogic (Nasdaq: SYBX) announced today that Richard Riese, M.D., Ph.D., Synlogic’s chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16th, 2020.

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) provides an update on its strategic plans and reports financial results for the three and twelve months ended December 31, 2019:

Medicus IT (MIT), a leading healthcare-focused managed services provider (MSP) based in Alpharetta, Georgia, announced the acquisition of Nexus Practice IT Services (Nexus).

Babson Diagnostics (Babson), a transformative diagnostic blood testing company, announced today that it has expanded its board of directors to include diagnostics industry leaders David Stein (Director), Dennis Gilbert (Director), and Dave Hickey (Observer).

Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of the Presto study by ENETS.

COCRYSTAL PHARMA, INC. announced registered direct offering with several institutional investors for 5,037,038 shares of its common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules.